Tag: common stock

WASHINGTON, D.C., July 10, 2025 (GLOBE NEWSWIRE) -- via IBN – On Thursday, July 10, 2025, Dickinson Wright filed a lawsuit on behalf of the law firm’s client, Datavault AI, Inc. (Nasdaq: DVLT), (Datavault AI), alleging securities fraud (stock manipulation), defamation and intentional tort against “John Doe” “naked” short sellers of Datavault AI common stock on the Nasdaq Stock Market. The Complaint alleges that the short sellers engaged in the unlawful practice of “naked short selling” and other manipulative devices – including marking the close, painting the tape, spoofing and layering. The Complaint further alleges that the “John Does” for themselves or acting in concert with the “naked” short sellers also published materially false and misleading and defamatory information on internet chat room “Stocktwits” and on LinkedIn. The lawsuit, filed in federal court in Chicago, seeks unspecified compensatory and special damages and other relief.

BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) plans to report Second Quarter 2025 financial results on Tuesday, August 5, 2025. Management will present the results during a conference call and webcast at 5:00 p.m. Eastern.

SAN DIEGO, July 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 102,350 shares of its common stock and granted an aggregate of 77,875 restricted stock unit (“RSU”) awards to 46 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform^™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).

Nasdaq compliance follows positive upward trend in Company’s Stock Price 

WALTHAM, Mass. and BOULDER, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its previously announced upsized underwritten public offering of 25,555,556 shares of its common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The public offering price was $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were sold by Cogent.